These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 222433)

  • 1. Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer.
    Yap HY; Blumenschein GR; Tashima CK; Hortobagyi GN; Buzdar AU; Wiseman CL
    Cancer; 1979 Jul; 44(1):32-4. PubMed ID: 222433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Combination chemotherapy with mitomycin C, methotrexate, and vincristine (MMV) for metastatic breast cancer refractory to adriamycin].
    Nomura Y; Kanda K; Tashiro H; Hamada Y; Saeki K
    Gan To Kagaku Ryoho; 1983 Mar; 10(3):824-8. PubMed ID: 6411002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial.
    Muss HB; White DR; Richards F; Cooper MR; Stuart JJ; Jackson DV; Rhyne L; Spurr CL
    Cancer; 1978 Nov; 42(5):2141-8. PubMed ID: 363253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive chemotherapy with cisplatin, mitoxantrone, methotrexate and vincristine in metastatic breast cancer.
    Queirolo P; Repetto L; Gardin G; Miglietta L; Guido T; Pronzato P; Rosso R
    J Chemother; 1991 Jun; 3(3):194-7. PubMed ID: 1919659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination chemotherapy for advanced breast cancer utilizing vincristine, adriamycin, and cyclophosphamide (VAC).
    Rainey JM; Jones SE; Salmon SE
    Cancer; 1979 Jan; 43(1):66-71. PubMed ID: 761176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combination chemotherapy with cyclophosphamide, methotrexate, 5-fluoro-uracil, and vincristine in solid metastasized tumours (author's transl)].
    Castor H; Fritsch H; Drings P; Moskwa G; von Kaick G
    Med Klin; 1974 Apr; 69(17):750-6. PubMed ID: 4837493
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination chemotherapy with vincristine, bleomycin, and methotrexate for advanced head and neck cancers.
    Woods RL; Stewart J; Fox RM; Tattersall MH
    Cancer Treat Rep; 1979; 63(11-12):1997-9. PubMed ID: 93514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer.
    Hortobagyi GN; Yap HY; Blumenschein GR; Buzdar AU; Barnes BC; Legha SS; Wiseman CL
    Cancer; 1983 Mar; 51(5):769-72. PubMed ID: 6600415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy in disseminated carcinoma of the breast.
    Kaufman S; Goldstein M
    Surg Gynecol Obstet; 1973 Jul; 137(1):83-6. PubMed ID: 4714324
    [No Abstract]   [Full Text] [Related]  

  • 10. Chemotherapy of metastatic breast cancer in postmenopausal women: a controlled trial of cyclophosphamide versus a five-drug combination of cyclophosphamide, vincristine, methotrexate, 5-fluorouracil and prednisone.
    Mouridsen HT; Palshof T
    Prog Clin Biol Res; 1977; 12():459-66. PubMed ID: 335404
    [No Abstract]   [Full Text] [Related]  

  • 11. MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
    Smith IE; Powles TJ
    Oncology; 1993 Apr; 50 Suppl 1():9-15. PubMed ID: 8483562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival.
    Manni A; Trujillo JE; Pearson OH
    Cancer Treat Rep; 1980 Jan; 64(1):111-6. PubMed ID: 6155207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.
    De Lena M; Brambilla C; Morabito A; Bonadonna G
    Cancer; 1975 Apr; 35(4):1108-15. PubMed ID: 1116104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cervix cancer: treatment with combination vincristine and high doses of methotrexate.
    Hakes T; Nikrui M; Magill G; Ochoa M
    Cancer; 1979 Feb; 43(2):459-64. PubMed ID: 421173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of combined vincristine, adriamycin, cyclophosphamide, and methotrexate with citrovorum factor factor rescue in metastatic breast cancer.
    Mattsson W; Arwidi A; von Eyben F; Lindholm CE
    Cancer Treat Rep; 1977 Nov; 61(8):1527-31. PubMed ID: 303543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose methotrexate for the remission induction of refractory adult acute lymphocytic leukemia.
    Peterson BA; Bloomfield CD
    Med Pediatr Oncol; 1978; 5(1):79-84. PubMed ID: 370537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin, vincristine, and cis-diamminedichloroplatinum (II) therapy in patients with advanced breast cancer.
    Trump DL; Ettinger DS; Abeloff MD
    Med Pediatr Oncol; 1981; 9(1):1-3. PubMed ID: 7007853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology.
    Canellos GP; Skarin AT; Rosenthal DS; Moloney WC; Frei E
    Cancer Treat Rep; 1981; 65 Suppl 1():125-9. PubMed ID: 6173118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy of metastatic breast cancer with vincristine adriamycin and prednisolone.
    Russell JA; Baker JW; Dady PJ; Ford HT; Gazet JC; McKinna JA; Nash AG; Powles TJ
    Cancer; 1978 Feb; 41(2):396-9. PubMed ID: 630530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer.
    Rischin D; Bishop JF; Olver IN; Laidlaw CR; Zimet A; Jeal P; Dipell JF
    Am J Clin Oncol; 1992 Oct; 15(5):392-4. PubMed ID: 1524039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.